Profound Medical Expands TULSA-PRO Use at Mount Sinai
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Profound Medical ( (TSE:PRN) ) is now available.
On January 15, 2026, Profound Medical announced that Mount Sinai Hospital in New York successfully treated its first prostate cancer patient using the company’s TULSA-PRO system, marking the first incision-free, AI-driven, MRI-guided TULSA Procedure for prostate disease in the New York Metro area. The collaboration between Mount Sinai’s urology and interventional radiology teams, which discharged the patient the same day, underscores the procedure’s potential clinical advantages—no blood loss, no hospital stay, faster recovery, and reduced risk of urinary incontinence and erectile dysfunction—strengthening Profound’s positioning in minimally invasive prostate care and expanding the clinical footprint of its TULSA-PRO technology at a top-ranked U.S. urology center.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$12.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
The score is held back primarily by persistent heavy losses and large cash burn despite strong revenue growth and improving gross margins. Technicals are supportive with a clear uptrend, and recent earnings commentary and events point to improving commercial traction and strengthened liquidity, but financing/dilution risk and lack of profitable valuation anchors keep the overall score in the mid-range.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Its flagship TULSA-PRO system delivers robotically controlled, transurethral ultrasound under real-time MRI guidance to treat a broad spectrum of prostate diseases while preserving urinary continence and sexual function, and its Sonalleve platform targets conditions such as uterine fibroids, adenomyosis, bone metastases pain, desmoid tumors, and osteoid osteoma across multiple global regulatory jurisdictions.
Average Trading Volume: 18,899
Technical Sentiment Signal: Buy
Current Market Cap: C$389M
For a thorough assessment of PRN stock, go to TipRanks’ Stock Analysis page.
